semustine has been researched along with Neoplasm Metastasis in 38 studies
Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU." | 7.67 | Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. ( Amato, DA; Cunningham, TJ; Falkson, G; Kaufman, JH; Von Hoff, DD, 1984) |
| "Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU)." | 7.66 | Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Schutt, AJ, 1982) |
| "To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients)." | 5.05 | Prolongation of the disease-free interval in surgically treated rectal carcinoma. ( , 1985) |
| "In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks." | 5.04 | Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2- ( Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978) |
| "One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU." | 3.67 | Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. ( Amato, DA; Cunningham, TJ; Falkson, G; Kaufman, JH; Von Hoff, DD, 1984) |
| "Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU)." | 3.66 | Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Schutt, AJ, 1982) |
| "Fifty-two untreated patients with colorectal cancer were randomized to receive 5-fluorouracil (5-FU) alternating either with methotrexate (MTX) or Baker's Antifol (BAF) with or without the immunostimulant, levamisole (Program I)." | 2.64 | Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole. ( Bedikian, AY; Bodey, GP; Burgess, MA; Mavligit, GM; Rodriguez, V; Valdivieso, M, 1978) |
| " Further, both disease staging and drug dosage have been shown to influence cure rates of combined-modality treatment." | 2.35 | Concepts for treatment of micrometastases developed in murine systems. ( Schabel, FM, 1976) |
| "Metastatic medulloblastoma is a rare clinical phenomenon." | 1.26 | Chemotherapeutic response in metastatic medulloblastoma: report of two cases and a review of the literature. ( Kovacs, SG; Nathanson, L, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (97.37) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kemeny, N | 2 |
| Yagoda, A | 2 |
| Braun, D | 2 |
| Von Hoff, DD | 1 |
| Amato, DA | 1 |
| Kaufman, JH | 1 |
| Falkson, G | 2 |
| Cunningham, TJ | 1 |
| Creagan, ET | 1 |
| Ahmann, DL | 2 |
| Schutt, AJ | 1 |
| Green, SJ | 1 |
| Breeden, JH | 1 |
| Vollmer, JT | 1 |
| Twomey, PL | 1 |
| Rivkin, SE | 1 |
| Gottlieb, JA | 2 |
| Thigpen, T | 1 |
| El Mawla, NG | 1 |
| Saiki, J | 1 |
| Dixon, DO | 1 |
| Enck, RE | 1 |
| Schabel, FM | 1 |
| Johnson, RJ | 1 |
| Einhorn, LH | 1 |
| Furnas, B | 1 |
| Costanza, ME | 1 |
| Nathanson, L | 2 |
| Schoenfeld, D | 1 |
| Wolter, J | 1 |
| Colsky, J | 1 |
| Regelson, W | 1 |
| Cunningham, T | 1 |
| Sedransk, N | 1 |
| Diggs, CH | 1 |
| Wiernik, PH | 1 |
| Smyth, AC | 1 |
| Hahn, RG | 2 |
| Temkin, NR | 1 |
| Savlov, ED | 1 |
| Perlia, C | 1 |
| Wampler, GL | 2 |
| Horton, J | 1 |
| Marsh, J | 1 |
| Carbone, PP | 1 |
| Bedikian, AY | 2 |
| Valdivieso, M | 2 |
| Mavligit, GM | 1 |
| Burgess, MA | 1 |
| Rodriguez, V | 1 |
| Bodey, GP | 2 |
| Douglass, HO | 1 |
| Lavin, PT | 1 |
| Woll, J | 1 |
| Conroy, JF | 1 |
| Carbone, P | 1 |
| Golbey, R | 1 |
| Weiss, RB | 1 |
| DeVita, VT | 1 |
| Khankhanian, N | 1 |
| Benjamin, RS | 1 |
| Berkelhammer, J | 1 |
| Mastrangelo, MJ | 1 |
| Bellet, RE | 1 |
| Berd, D | 1 |
| Prehn, RT | 1 |
| Hasegawa, H | 1 |
| Shapiro, WR | 1 |
| Posner, JB | 1 |
| Kovacs, SG | 1 |
| Lee, W | 1 |
| Moore, RP | 1 |
| DiBenedetto, J | 1 |
| Moayeri, H | 1 |
| Evans, JT | 1 |
| Mittelman, A | 1 |
| Greco, FA | 1 |
| Richardson, RL | 1 |
| Shulman, SF | 1 |
| Oldham, RK | 1 |
| Day, TG | 1 |
| Wharton, JT | 1 |
| Rutledge, FN | 1 |
| Bisel, HF | 1 |
| Edmonson, JH | 1 |
| Eagan, RT | 1 |
| O'Connell, MJ | 1 |
| Frytak, S | 1 |
| Baker, LH | 1 |
| Talley, RW | 1 |
| Matter, R | 1 |
| Lehane, DE | 1 |
| Ruffner, BW | 1 |
| Jones, SE | 1 |
| Morrison, FS | 1 |
| Stephens, RL | 1 |
| Gehan, EA | 1 |
| Vaitkevicius, VK | 1 |
| Falkson, HC | 1 |
| Wittes, RE | 1 |
| Hong, WK | 1 |
| Gatchell, L | 1 |
| Krakoff, IH | 1 |
| Golbey, RB | 1 |
| Greager, JA | 1 |
| Culberson, G | 1 |
| Manning, B | 1 |
| Das Cupta, TK | 1 |
| Dorn, W | 1 |
| Gladden, MP | 1 |
| Rankin, EA | 1 |
| Luce, JK | 1 |
| Carter, SK | 2 |
| Buroker, TR | 1 |
| Moertel, CG | 1 |
| Fleming, TR | 1 |
| Everson, LK | 1 |
| Cullinan, SA | 1 |
| Krook, JE | 1 |
| Mailliard, JA | 1 |
| Marschke, RF | 1 |
| Klaassen, DJ | 1 |
| Laurie, JA | 1 |
| Mayer, RJ | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Spreafico, F | 1 |
| Garattini, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
4 reviews available for semustine and Neoplasm Metastasis
| Article | Year |
|---|---|
[Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994].
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1995 |
Concepts for treatment of micrometastases developed in murine systems.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Cricetinae; Cyclop | 1976 |
Methyl-CCNU inclinical cancer therapy.
Topics: Animals; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous | 1974 |
Selective antimetastatic treatment--current status and future prospects.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cyclophosphamide; Drug Evaluation, Preclinical; Humans; Immunothe | 1974 |
15 trials available for semustine and Neoplasm Metastasis
| Article | Year |
|---|---|
Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1983 |
Gastrointestinal cancer--colon (surgery-radiotherapy). The role of radiation therapy in the management of rectosigmoid cancer.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Neoplasm Me | 1977 |
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leuko | 1977 |
Results with methyl-CCNU and DTIC in metastatic melanoma.
Topics: Brain Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dacarbazine; Drug | 1977 |
Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Humans; Kidney | 1978 |
Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neopl | 1978 |
Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1978 |
A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; D | 1979 |
The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Colonic N | 1979 |
Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cell Line; Cytotoxicity, Immunologic; Drug Therapy, | 1979 |
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug | 1976 |
Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; | 1976 |
Fluorouracil, methyl-CCNU and vincristine in cancer of the colon.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neopla | 1976 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluat | 1985 |
19 other studies available for semustine and Neoplasm Metastasis
| Article | Year |
|---|---|
Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis | 1984 |
Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukocyte Count; Leukopenia; Male; | 1982 |
Toxicity of very high dose nitrosourea administration.
Topics: Adenocarcinoma; Bone Marrow; Colonic Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitr | 1982 |
Methyl CCNU and adriamycin for patients with metastatic sarcomas: a Southwest Oncology Group study.
Topics: Age Factors; Bone Neoplasms; Doxorubicin; Drug Therapy, Combination; Gastrointestinal Diseases; Huma | 1980 |
Mallory-Weiss lesion following cancer chemotherapy.
Topics: Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms; Male; Mallory-Weiss Syndrome; Methy | 1977 |
Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1977 |
Chemotherapy for sarcoma of the stomach.
Topics: Adult; Aged; Asparaginase; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Drug Therapy, C | 1979 |
Chemotherapy of experimental metastatic brain tumors in female Wistar rats.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma 256, Walker; Carotid Arteries; Cells, Cul | 1979 |
Chemotherapeutic response in metastatic medulloblastoma: report of two cases and a review of the literature.
Topics: Adolescent; Adult; Bone Neoplasms; Brain Neoplasms; Cyclophosphamide; Dactinomycin; Drug Therapy, Co | 1978 |
Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy.
Topics: Brain Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Pu | 1978 |
Phase II study of melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1978 |
Combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Chemotherapy for squamous carcinoma of the cervix: doxorubicin--methyl CCNU.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middl | 1978 |
Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
Topics: Bone Marrow; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Met | 1977 |
Chemotherapy, BCG, and serum from tumor-bearing mice: comparative effects on growth and spread of mouse Lewis lung cancer.
Topics: Animals; BCG Vaccine; Cyclophosphamide; Disease Models, Animal; Hindlimb; Immunotherapy; L-Lactate D | 1975 |
Regression of a renal-cell metastatic osseous lesion following treatment.
Topics: Adenocarcinoma; Bone Neoplasms; Humans; Humerus; Kidney Neoplasms; Male; Medroxyprogesterone; Middle | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D | 1975 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Adjuvant therapy in rectal cancer: a protocol proposal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Inf | 1985 |